Skip to main content
Erschienen in: Endocrine 1/2014

01.02.2014 | Original Article

Circulating glucagon to ghrelin ratio as a determinant of insulin resistance in hyperthyroidism

verfasst von: Kemal Ağbaht, Murat Faik Erdogan, Rifat Emral, Nilgun Baskal, Sevim Güllü

Erschienen in: Endocrine | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Due to stimulated overall metabolism, a state of nutritional inadequacy often ensues, during thyrotoxicosis. We aimed to investigate circulating levels of some major components of the system that regulates energy stores, glucose, and fat metabolism, during thyrotoxicosis compared to euthyroidism. Fasting serum ghrelin, leptin, adiponectin, insulin, glucagon, glucose, as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter). The same measurements were repeated an average 3 months later, when all patients achieved euthyroidism. Compared to euthyroidism, in thyrotoxicosis, patients had lower ghrelin and fat mass; had comparable insulin, HOMA-IR, glucagon, and leptin levels; higher levels of circulating adiponectin. Fasting serum glucose tended to be higher during thyrotoxicosis. The unique correlation of HOMA-IR was with the-glucagon to ghrelin ratio-(r = 0.801, p < 0.001) in hyperthyrodism, and with glucagon itself in euthyroidism (r = −0.844, p < 0.001). Circulating levels of ghrelin are decreased; leptin, insulin, glucagon are unchanged; adiponectin are increased during hyperthyroidism. The fasting HOMA-IR tends to be higher, despite the decreased adiposity in hyperthyroidism. The-glucagon to ghrelin ratio-strongly correlates with fasting HOMA-IR in hyperthyroidism.
Literatur
2.
Zurück zum Zitat M.W. Schwartz, S.C. Woods, D. Porte Jr, R.J. Seeley, D.G. Baskin, Central nervous system control of food intake. Nature 404, 661–671 (2000)PubMed M.W. Schwartz, S.C. Woods, D. Porte Jr, R.J. Seeley, D.G. Baskin, Central nervous system control of food intake. Nature 404, 661–671 (2000)PubMed
3.
Zurück zum Zitat A. Sainsbury, G.J. Cooney, H. Herzog, Hypothalamic regulation of energy homeostasis. Best Pract. Res. Clin. Endocrinol. Metab. 16, 623–637 (2002)PubMedCrossRef A. Sainsbury, G.J. Cooney, H. Herzog, Hypothalamic regulation of energy homeostasis. Best Pract. Res. Clin. Endocrinol. Metab. 16, 623–637 (2002)PubMedCrossRef
4.
Zurück zum Zitat S.M. Poykko, E. Kellokoski, S. Horkko, H. Kauma, Y.A. Kesaniemi, O. Ukkola, Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52, 2546–2553 (2003)PubMedCrossRef S.M. Poykko, E. Kellokoski, S. Horkko, H. Kauma, Y.A. Kesaniemi, O. Ukkola, Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52, 2546–2553 (2003)PubMedCrossRef
5.
Zurück zum Zitat A. Ikezaki, H. Hosoda, K. Ito, S. Iwama, N. Miura, H. Matsuoka, C. Kondo, M. Kojima, K. Kangawa, S. Sugihara, Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes 51, 3408–3411 (2002)PubMedCrossRef A. Ikezaki, H. Hosoda, K. Ito, S. Iwama, N. Miura, H. Matsuoka, C. Kondo, M. Kojima, K. Kangawa, S. Sugihara, Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes 51, 3408–3411 (2002)PubMedCrossRef
6.
Zurück zum Zitat Y. Li, J. Hai, L. Li, X. Chen, H. Peng, M. Cao, Q. Zhang, Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development. Endocrine 43(2), 376–386 (2012)PubMedCrossRef Y. Li, J. Hai, L. Li, X. Chen, H. Peng, M. Cao, Q. Zhang, Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development. Endocrine 43(2), 376–386 (2012)PubMedCrossRef
7.
Zurück zum Zitat B.W. Liu, Q. Lu, C.M. Ma, J.R. Liu, D.H. Lou, X.L. Liu, F.Z. Yin, The study of soluble intercellular adhesion molecule-1 and ghrelin in adolescents with family history of type 2 diabetes. Endocrine 42, 599–605 (2012)PubMedCrossRef B.W. Liu, Q. Lu, C.M. Ma, J.R. Liu, D.H. Lou, X.L. Liu, F.Z. Yin, The study of soluble intercellular adhesion molecule-1 and ghrelin in adolescents with family history of type 2 diabetes. Endocrine 42, 599–605 (2012)PubMedCrossRef
8.
Zurück zum Zitat P.J. Delhanty, A.J. van der Lely, Ghrelin: a new treatment for non-alcoholic fatty liver disease? Endocrine 43(2), 247–248 (2012)PubMedCrossRef P.J. Delhanty, A.J. van der Lely, Ghrelin: a new treatment for non-alcoholic fatty liver disease? Endocrine 43(2), 247–248 (2012)PubMedCrossRef
9.
Zurück zum Zitat J.C. Chuang, I. Sakata, D. Kohno, M. Perello, S. Osborne-Lawrence, J.J. Repa, J.M. Zigman, Ghrelin directly stimulates glucagon secretion from pancreatic alpha-cells. Mol. Endocrinol. 25, 1600–1611 (2011)PubMedCrossRef J.C. Chuang, I. Sakata, D. Kohno, M. Perello, S. Osborne-Lawrence, J.J. Repa, J.M. Zigman, Ghrelin directly stimulates glucagon secretion from pancreatic alpha-cells. Mol. Endocrinol. 25, 1600–1611 (2011)PubMedCrossRef
10.
Zurück zum Zitat M.A. Arafat, B. Otto, H. Rochlitz, M. Tschop, V. Bahr, M. Mohlig, S. Diederich, J. Spranger, A.F. Pfeiffer, Glucagon inhibits ghrelin secretion in humans. Eur. J. Endocrinol. 153, 397–402 (2005)PubMedCrossRef M.A. Arafat, B. Otto, H. Rochlitz, M. Tschop, V. Bahr, M. Mohlig, S. Diederich, J. Spranger, A.F. Pfeiffer, Glucagon inhibits ghrelin secretion in humans. Eur. J. Endocrinol. 153, 397–402 (2005)PubMedCrossRef
11.
Zurück zum Zitat A.E. Altinova, F.B. Toruner, M. Akturk, S. Elbeg, I. Yetkin, N. Cakir, M. Arslan, Reduced serum acylated ghrelin levels in patients with hyperthyroidism. Horm. Res. 65, 295–299 (2006)PubMedCrossRef A.E. Altinova, F.B. Toruner, M. Akturk, S. Elbeg, I. Yetkin, N. Cakir, M. Arslan, Reduced serum acylated ghrelin levels in patients with hyperthyroidism. Horm. Res. 65, 295–299 (2006)PubMedCrossRef
12.
Zurück zum Zitat O. Gimenez-Palop, G. Gimenez-Perez, D. Mauricio, E. Berlanga, N. Potau, C. Vilardell, J. Arroyo, J.M. Gonzalez-Clemente, A. Caixas, Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger, food intake or anthropometric changes. Eur. J. Endocrinol. 153, 73–79 (2005)PubMedCrossRef O. Gimenez-Palop, G. Gimenez-Perez, D. Mauricio, E. Berlanga, N. Potau, C. Vilardell, J. Arroyo, J.M. Gonzalez-Clemente, A. Caixas, Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger, food intake or anthropometric changes. Eur. J. Endocrinol. 153, 73–79 (2005)PubMedCrossRef
13.
Zurück zum Zitat A.L. Riis, T.K. Hansen, N. Moller, J. Weeke, J.O. Jorgensen, Hyperthyroidism is associated with suppressed circulating ghrelin levels. J. Clin. Endocrinol. Metab. 88, 853–857 (2003)PubMedCrossRef A.L. Riis, T.K. Hansen, N. Moller, J. Weeke, J.O. Jorgensen, Hyperthyroidism is associated with suppressed circulating ghrelin levels. J. Clin. Endocrinol. Metab. 88, 853–857 (2003)PubMedCrossRef
14.
Zurück zum Zitat G. Dimitriadis, E. Hatziagelaki, P. Mitrou, V. Lambadiari, E. Maratou, A.E. Raptis, J.E. Gerich, S.A. Raptis, Effect of hyperthyroidism on clearance and secretion of glucagon in man. Exp. Clin. Endocrinol. Diabetes 119, 214–217 (2011)PubMedCrossRef G. Dimitriadis, E. Hatziagelaki, P. Mitrou, V. Lambadiari, E. Maratou, A.E. Raptis, J.E. Gerich, S.A. Raptis, Effect of hyperthyroidism on clearance and secretion of glucagon in man. Exp. Clin. Endocrinol. Diabetes 119, 214–217 (2011)PubMedCrossRef
15.
Zurück zum Zitat N. Pontikides, G.E. Krassas, Basic endocrine products of adipose tissue in states of thyroid dysfunction. Thyroid 17, 421–431 (2007)PubMedCrossRef N. Pontikides, G.E. Krassas, Basic endocrine products of adipose tissue in states of thyroid dysfunction. Thyroid 17, 421–431 (2007)PubMedCrossRef
16.
Zurück zum Zitat D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)PubMedCrossRef D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)PubMedCrossRef
17.
Zurück zum Zitat M. Tschop, C. Weyer, P.A. Tataranni, V. Devanarayan, E. Ravussin, M.L. Heiman, Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707–709 (2001)PubMedCrossRef M. Tschop, C. Weyer, P.A. Tataranni, V. Devanarayan, E. Ravussin, M.L. Heiman, Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707–709 (2001)PubMedCrossRef
18.
Zurück zum Zitat J. Nedvidkova, I. Krykorkova, V. Bartak, H. Papezova, P.W. Gold, S. Alesci, K. Pacak, Loss of meal-induced decrease in plasma ghrelin levels in patients with anorexia nervosa. J. Clin. Endocrinol. Metab. 88, 1678–1682 (2003)PubMedCrossRef J. Nedvidkova, I. Krykorkova, V. Bartak, H. Papezova, P.W. Gold, S. Alesci, K. Pacak, Loss of meal-induced decrease in plasma ghrelin levels in patients with anorexia nervosa. J. Clin. Endocrinol. Metab. 88, 1678–1682 (2003)PubMedCrossRef
19.
Zurück zum Zitat S. Rojdmark, J. Calissendorff, O. Danielsson, K. Brismar, Hunger-satiety signals in patients with Graves’ thyrotoxicosis before, during, and after long-term pharmacological treatment. Endocrine 27, 55–61 (2005)PubMedCrossRef S. Rojdmark, J. Calissendorff, O. Danielsson, K. Brismar, Hunger-satiety signals in patients with Graves’ thyrotoxicosis before, during, and after long-term pharmacological treatment. Endocrine 27, 55–61 (2005)PubMedCrossRef
20.
Zurück zum Zitat J. Kosowicz, A. Baumann-Antczak, M. Ruchala, M. Gryczynska, E. Gurgul, J. Sowinski, Thyroid hormones affect plasma ghrelin and obestatin levels. Horm. Metab. Res. 43, 121–125 (2011)PubMedCrossRef J. Kosowicz, A. Baumann-Antczak, M. Ruchala, M. Gryczynska, E. Gurgul, J. Sowinski, Thyroid hormones affect plasma ghrelin and obestatin levels. Horm. Metab. Res. 43, 121–125 (2011)PubMedCrossRef
21.
Zurück zum Zitat K. Dezaki, H. Sone, T. Yada, Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol. Ther. 118, 239–249 (2008)PubMedCrossRef K. Dezaki, H. Sone, T. Yada, Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol. Ther. 118, 239–249 (2008)PubMedCrossRef
22.
Zurück zum Zitat G. Dimitriadis, B. Baker, H. Marsh, L. Mandarino, R. Rizza, R. Bergman, M. Haymond, J. Gerich, Effect of thyroid hormone excess on action, secretion, and metabolism of insulin in humans. Am. J. Physiol. 248, E593–E601 (1985)PubMed G. Dimitriadis, B. Baker, H. Marsh, L. Mandarino, R. Rizza, R. Bergman, M. Haymond, J. Gerich, Effect of thyroid hormone excess on action, secretion, and metabolism of insulin in humans. Am. J. Physiol. 248, E593–E601 (1985)PubMed
23.
Zurück zum Zitat P. Mitrou, S.A. Raptis, G. Dimitriadis, Insulin action in hyperthyroidism: a focus on muscle and adipose tissue. Endocr. Rev. 31, 663–679 (2010)PubMedCrossRef P. Mitrou, S.A. Raptis, G. Dimitriadis, Insulin action in hyperthyroidism: a focus on muscle and adipose tissue. Endocr. Rev. 31, 663–679 (2010)PubMedCrossRef
24.
Zurück zum Zitat G. Dimitriadis, P. Mitrou, V. Lambadiari, E. Boutati, E. Maratou, E. Koukkou, M. Tzanela, N. Thalassinos, S.A. Raptis, Glucose and lipid fluxes in the adipose tissue after meal ingestion in hyperthyroidism. J. Clin. Endocrinol. Metab. 91, 1112–1118 (2006)PubMedCrossRef G. Dimitriadis, P. Mitrou, V. Lambadiari, E. Boutati, E. Maratou, E. Koukkou, M. Tzanela, N. Thalassinos, S.A. Raptis, Glucose and lipid fluxes in the adipose tissue after meal ingestion in hyperthyroidism. J. Clin. Endocrinol. Metab. 91, 1112–1118 (2006)PubMedCrossRef
25.
Zurück zum Zitat U.M. Kabadi, A.B. Eisenstein, Glucose intolerance in hyperthyroidism: role of glucagon. J. Clin. Endocrinol. Metab. 50, 392–396 (1980)PubMedCrossRef U.M. Kabadi, A.B. Eisenstein, Glucose intolerance in hyperthyroidism: role of glucagon. J. Clin. Endocrinol. Metab. 50, 392–396 (1980)PubMedCrossRef
26.
Zurück zum Zitat U.M. Kabadi, A.B. Eisenstein, Impaired pancreatic alpha-cell response in hyperthyroidism. J. Clin. Endocrinol. Metab. 51, 478–482 (1980)PubMedCrossRef U.M. Kabadi, A.B. Eisenstein, Impaired pancreatic alpha-cell response in hyperthyroidism. J. Clin. Endocrinol. Metab. 51, 478–482 (1980)PubMedCrossRef
27.
Zurück zum Zitat J.E. Gerich, M. Langlois, C. Noacco, V. Schneider, P.H. Forsham, Adrenergic modulation of pancreatic glucagon secretion in man. J. Clin. Invest. 53, 1441–1446 (1974)PubMedCentralPubMedCrossRef J.E. Gerich, M. Langlois, C. Noacco, V. Schneider, P.H. Forsham, Adrenergic modulation of pancreatic glucagon secretion in man. J. Clin. Invest. 53, 1441–1446 (1974)PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat P. Iglesias, J.J. Diez, Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine 40, 61–70 (2007)PubMedCrossRef P. Iglesias, J.J. Diez, Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine 40, 61–70 (2007)PubMedCrossRef
29.
Zurück zum Zitat H. Wahrenberg, A. Wennlund, J. Hoffstedt, Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves’ hyperthyroidism. Eur. J. Endocrinol. 146, 607–611 (2002)PubMedCrossRef H. Wahrenberg, A. Wennlund, J. Hoffstedt, Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves’ hyperthyroidism. Eur. J. Endocrinol. 146, 607–611 (2002)PubMedCrossRef
30.
Zurück zum Zitat R. Seven, Thyroid status and leptin in Basedow-Graves and multinodular goiter patients. J. Toxicol. Environ. Health A. 63, 575–581 (2001)PubMedCrossRef R. Seven, Thyroid status and leptin in Basedow-Graves and multinodular goiter patients. J. Toxicol. Environ. Health A. 63, 575–581 (2001)PubMedCrossRef
31.
Zurück zum Zitat S. Corbetta, P. Englaro, S. Giambona, L. Persani, W.F. Blum, P. Beck-Peccoz, Lack of effects of circulating thyroid hormone levels on serum leptin concentrations. Eur. J. Endocrinol. 137, 659–663 (1997)PubMedCrossRef S. Corbetta, P. Englaro, S. Giambona, L. Persani, W.F. Blum, P. Beck-Peccoz, Lack of effects of circulating thyroid hormone levels on serum leptin concentrations. Eur. J. Endocrinol. 137, 659–663 (1997)PubMedCrossRef
32.
Zurück zum Zitat S. Yaturu, S. Prado, S.R. Grimes, Changes in adipocyte hormones leptin, resistin, and adiponectin in thyroid dysfunction. J. Cell. Biochem. 93, 491–496 (2004)PubMedCrossRef S. Yaturu, S. Prado, S.R. Grimes, Changes in adipocyte hormones leptin, resistin, and adiponectin in thyroid dysfunction. J. Cell. Biochem. 93, 491–496 (2004)PubMedCrossRef
34.
Zurück zum Zitat R. Coppari, M. Ichinose, C.E. Lee, A.E. Pullen, C.D. Kenny, R.A. McGovern, V. Tang, S.M. Liu, T. Ludwig, S.C. Chua Jr, B.B. Lowell, J.K. Elmquist, The hypothalamic arcuate nucleus: a key site for mediating leptin’s effects on glucose homeostasis and locomotor activity. Cell Metab. 1, 63–72 (2005)PubMedCrossRef R. Coppari, M. Ichinose, C.E. Lee, A.E. Pullen, C.D. Kenny, R.A. McGovern, V. Tang, S.M. Liu, T. Ludwig, S.C. Chua Jr, B.B. Lowell, J.K. Elmquist, The hypothalamic arcuate nucleus: a key site for mediating leptin’s effects on glucose homeostasis and locomotor activity. Cell Metab. 1, 63–72 (2005)PubMedCrossRef
35.
Zurück zum Zitat N. Kubota, W. Yano, T. Kubota, T. Yamauchi, S. Itoh, H. Kumagai, H. Kozono, I. Takamoto, S. Okamoto, T. Shiuchi, R. Suzuki, H. Satoh, A. Tsuchida, M. Moroi, K. Sugi, T. Noda, H. Ebinuma, Y. Ueta, T. Kondo, E. Araki, O. Ezaki, R. Nagai, K. Tobe, Y. Terauchi, K. Ueki, Y. Minokoshi, T. Kadowaki, Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 6, 55–68 (2007)PubMedCrossRef N. Kubota, W. Yano, T. Kubota, T. Yamauchi, S. Itoh, H. Kumagai, H. Kozono, I. Takamoto, S. Okamoto, T. Shiuchi, R. Suzuki, H. Satoh, A. Tsuchida, M. Moroi, K. Sugi, T. Noda, H. Ebinuma, Y. Ueta, T. Kondo, E. Araki, O. Ezaki, R. Nagai, K. Tobe, Y. Terauchi, K. Ueki, Y. Minokoshi, T. Kadowaki, Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 6, 55–68 (2007)PubMedCrossRef
36.
Zurück zum Zitat T. Saito, T. Kawano, A. Ikoma, K. Namai, H. Tamemoto, M. Kawakami, S.E. Ishikawa, Elevation of serum adiponectin levels in Basedow disease. Metabolism 54, 1461–1466 (2005)PubMedCrossRef T. Saito, T. Kawano, A. Ikoma, K. Namai, H. Tamemoto, M. Kawakami, S.E. Ishikawa, Elevation of serum adiponectin levels in Basedow disease. Metabolism 54, 1461–1466 (2005)PubMedCrossRef
Metadaten
Titel
Circulating glucagon to ghrelin ratio as a determinant of insulin resistance in hyperthyroidism
verfasst von
Kemal Ağbaht
Murat Faik Erdogan
Rifat Emral
Nilgun Baskal
Sevim Güllü
Publikationsdatum
01.02.2014
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2014
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-9951-9

Weitere Artikel der Ausgabe 1/2014

Endocrine 1/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.